Editas Medicine, Inc. develops genome editing medicines using CRISPR systems for serious diseases. Company news centers on its in vivo pipeline, including EDIT-401, an LDLR-targeted development candidate designed to treat hyperlipidemia by increasing LDLR protein expression and reducing LDL cholesterol.
Recurring updates include quarterly financial results, business highlights, scientific conference presentations, preclinical data for EDIT-401, intellectual property developments involving CRISPR/Cas9 patent interference, and investor conference participation. The company also reports on pipeline prioritization and its licensed Cas12a and Cas9 patent estates for human medicines.
Editas Medicine announced leadership appointments, including Jim Mullen as CEO and Lisa Michaels, M.D., as CMO. The company initiated adult mid-dose dosing in the BRILLIANCE trial for EDIT-101 and launched the Phase 1/2 RUBY trial for EDIT-301 targeting sickle cell disease. Editas ended 2020 with $512 million in cash and added $250 million from a public offering. For Q4 2020, the net loss was $62.5 million on revenues of $11.4 million, a drop from the previous year due to the termination of its Allergan collaboration.
Editas Medicine will host a conference call and webcast on February 25, 2021, at 8:00 a.m. ET to discuss a corporate update and its fourth quarter and full year 2020 results. Investors can join through the US toll-free number (844) 348-3801 or internationally at (213) 358-0955, using Conference ID 7172199. The webcast will also be available on Editas Medicine's website.
Editas is focused on genome editing technologies, including CRISPR, aimed at developing treatments for serious genetic diseases.
Editas Medicine announces the appointment of James C. Mullen as Chief Executive Officer, effective February 15, 2021. Mullen, who has served as Chairman since March 2018, will succeed Cindy Collins, who played a pivotal role in advancing the company's clinical trials, including the initiation of the EDIT-101 trial. Under Collins, the company also recovered rights to ocular programs and expanded its pipeline. Mullen aims to lead Editas in developing transformative gene-edited medicines for serious diseases, continuing the company's growth trajectory.
Editas Medicine (Nasdaq: EDIT) announced an underwritten offering of 3,500,000 shares of common stock priced at $66.00 per share, aiming for gross proceeds of approximately $231.0 million. This offering is subject to a 30-day option for underwriters to purchase an additional 525,000 shares. The deal is expected to close around January 25, 2021, pending customary conditions. J.P. Morgan and Morgan Stanley are leading the offering, with a preliminary prospectus filed with the SEC. Editas focuses on gene editing for treating serious diseases.
Editas Medicine intends to offer 3,500,000 shares of its common stock in an underwritten public offering, with an option for underwriters to purchase an additional 525,000 shares. The offering comes amidst market conditions and is managed by J.P. Morgan and Morgan Stanley, among others. The company has an effective shelf registration with the SEC from March 2018. Editas focuses on CRISPR gene-editing technologies to develop treatments for serious diseases, but the actual success of this offering depends on various market conditions.
Editas Medicine provides updates on its ocular and blood disease programs, highlighting progress in its clinical trials. The company plans to accelerate enrollment in the Phase 1/2 BRILLIANCE trial for EDIT-101 and is set to dose the first patient in the adult mid-dose cohort within Q1 2021. EDIT-301 will begin dosing for sickle cell disease patients in 2021, with an IND filing for beta-thalassemia expected by year-end. Future goals include declaring a candidate for autosomal dominant retinitis pigmentosa and advancing solid tumor treatments.
Editas Medicine has announced FDA clearance to begin the safety phase of its EDIT-301 clinical trial for sickle cell disease, marking a significant milestone for the company and potential patients. EDIT-301, an experimental gene editing therapy, is developed using CRISPR/Cas12a technology and aims to address the unmet medical needs of those suffering from this inherited disorder. The company is preparing to initiate the RUBY trial, which will assess both the safety and efficacy of EDIT-301. An improved potency assay will be required before moving to the efficacy phase.
Editas Medicine (Nasdaq: EDIT) announced the resignation of Chief Scientific Officer Charles Albright, effective January 15, 2021. A search for his successor is currently in progress. Albright has been pivotal in advancing Editas's genomic medicine initiatives and CRISPR gene editing programs. The company focuses on developing transformative genomic medicines aimed at serious diseases worldwide. While the transition may pose challenges, Editas continues its commitment to innovation in the field of genome editing.
Editas Medicine (Nasdaq: EDIT) announced it will present an overview at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 10:50 a.m. ET. The event will be held virtually, and a live webcast will be accessible on Editas Medicine's website, with an archived replay available for 30 days post-presentation. As a leader in genome editing, Editas focuses on CRISPR technologies to develop precision genomic medicines for serious diseases globally.
Editas Medicine (NASDAQ: EDIT) has appointed Meeta Chatterjee, Ph.D., to its Board of Directors. Dr. Chatterjee brings over 30 years of experience in biopharmaceuticals, focusing on research, development, mergers, and acquisitions. She currently serves as Senior VP of Global Business Development at Legend Biotech. Her previous role at Merck involved overseeing critical business development transactions. This strategic addition aims to enhance Editas’ leadership and bolster its goal of advancing CRISPR technology for treating serious diseases.